BACKGROUND: Peripheral arterial disease remains a significant global health burden despite revolutionary improvements in endovascular techniques over the past decade. The durability of intervention for critical limb ischaemia is poor, and the condition is associated with high morbidity and mortality rates. To address this deficiency, alternative therapeutic options are being explored. Advances in the fields of gene therapy and therapeutic angiogenesis have led to these being advocated as potential future treatments. METHODS: Relevant medical literature from PubMed, Embase, the Cochrane Library and Google Scholar from the inception of these databases to June 2011 was reviewed. RESULTS: Encouraging outcomes in preclinical trials using a variety of proangiogenic growth factors have led to numerous efficacy and safety studies. However, no clinical study has shown significant benefit for gene therapy over placebo. CONCLUSION: Identifying the optimal site for gene delivery, choice of vector and duration of treatment is needed if gene therapy is to become a credible therapeutic option for peripheral arterial disease.
BACKGROUND: Peripheral arterial disease remains a significant global health burden despite revolutionary improvements in endovascular techniques over the past decade. The durability of intervention for critical limb ischaemia is poor, and the condition is associated with high morbidity and mortality rates. To address this deficiency, alternative therapeutic options are being explored. Advances in the fields of gene therapy and therapeutic angiogenesis have led to these being advocated as potential future treatments. METHODS: Relevant medical literature from PubMed, Embase, the Cochrane Library and Google Scholar from the inception of these databases to June 2011 was reviewed. RESULTS: Encouraging outcomes in preclinical trials using a variety of proangiogenic growth factors have led to numerous efficacy and safety studies. However, no clinical study has shown significant benefit for gene therapy over placebo. CONCLUSION: Identifying the optimal site for gene delivery, choice of vector and duration of treatment is needed if gene therapy is to become a credible therapeutic option for peripheral arterial disease.
Authors: Amanda J LeBlanc; Laxminarayanan Krishnan; Christopher J Sullivan; Stuart K Williams; James B Hoying Journal: Microcirculation Date: 2012-11 Impact factor: 2.628
Authors: Fernando A Fierro; Nataly Magner; Julie Beegle; Heather Dahlenburg; Jeannine Logan White; Ping Zhou; Karen Pepper; Brian Fury; Dane Philip Coleal-Bergum; Gerhard Bauer; William Gruenloh; Geralyn Annett; Christy Pifer; Jan A Nolta Journal: Transfusion Date: 2018-11-01 Impact factor: 3.157
Authors: Jan Skóra; Artur Pupka; Dariusz Janczak; Piotr Barć; Tomasz Dawiskiba; Krzysztof Korta; Dagmara Baczyńska; Agnieszka Mastalerz-Migas; Jerzy Garcarek Journal: Arch Med Sci Date: 2014-07-23 Impact factor: 3.318